Autologous mesothelin-targeted CAR-T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous mesothelin-targeted CAR-T cells, covering 2025-10-08 to 2025-10-08. Get the full timeline:
Most recent: Clinical Trial Update: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin [Phase 1, Phase 2]